RxDoctor Payments Data

Brett Brewer, MD

Internal Medicine · Snowflake, AZNPI 1538516778

Payments from drug & device makers

$1,435in general payments, 2019–2025

Across 80 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$353
  • AstraZeneca$287
  • Novo Nordisk$151
  • Lilly USA, LLC$148
  • Exact Sciences$95
  • Xeris Pharmaceuticals, Inc.$79
  • plus $322 from 12 others

What the payments were for

  • Food & beverage$1,435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,435 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$2,607
Medicare patients
65
Services billed
133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$172,089
OzempicSemaglutide65$62,687
JardianceEmpagliflozin46$53,726
XareltoRivaroxaban35$52,484
MounjaroTirzepatide37$43,434
TrulicityDulaglutide23$29,997
Soliqua 100-33Insulin Glargine/Lixisenatide23$26,067
FarxigaDapagliflozin Propanediol13$18,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,266
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$15,990
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$11,820
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,668
InvokanaCanagliflozin12$6,966
GemtesaVibegron12$5,996
Atorvastatin Calcium597$5,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$353$172,089116 claims
Lilly USA, LLCMounjaro, Trulicity$148$73,43160 claims
Novo NordiskOzempic$151$62,68765 claims
Johnson & JohnsonXarelto, Invokana$71$59,45047 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$13$31,57740 claims
AstraZenecaFarxiga, Breztri Aerosphere$287$29,18930 claims
GSKTrelegy Ellipta$19$17,26623 claims
Sumitomo Pharma America, Inc.Gemtesa$52$5,99612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Snowflake

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →